help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halmos, G.
Right arrow Articles by Nagy, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halmos, G.
Right arrow Articles by Nagy, A.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 10 3509-3512
Copyright © 2000 by The Endocrine Society

Special Articles

RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors

Gabor Halmos, Baodong Sun, Andrew V. Schally, Francine Hebert and Attila Nagy


   Abstract
Top
 Abstract
 
ABSTRACT. Characteristics of receptors for somatostatin (SST) analog RC-160 on 17 surgical specimens of human epithelial ovarian cancer and two human ovarian cancer lins were determined by ligand competition assays. The expression of mRNA for four SST receptor subrypes (sst1, sst3, sst2A, sst5) was investigated by RT-PCR. Thirteen of 17 specimens (76%) exhibited high affinity binding sites for RC-160 with Kd = 6.55 nmol/L and a Bmax = 575.4 fmol/mg membrane protein. Specific receptors for RC-160 were also found in xenografts of OV-1063 and UCI-107 human ovarian cancer lines. The mRNA for sst1 was detected in 65% of the ovarian cancer specimens, while the incidence ov sst2A, sst3, and sst5 was 65%, 41% and 24%, respectively. Both ovarian cancer cell lines also expressed mRNA for these four subtypes. The presence of these SST receptor subtypes in human ovarian cancers allows the use of SST analogs and their radionuclide and cytoxic derivatives for the diagnosis and treatment of this malignancy.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Buchholz, G. Keller, A. V. Schally, G. Halmos, F. Hohla, E. Heinrich, F. Koester, B. Baker, and J. B. Engel
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations
PNAS, July 5, 2006; 103(27): 10403 - 10407.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke
Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Szepeshazi, A. V. Schally, G. Halmos, P. Armatis, F. Hebert, B. Sun, A. Feil, H. Kiaris, and A. Nagy
Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Somatostatin Receptor-positive Experimental Colon Cancers Independently of Their p53 Status
Cancer Res., February 1, 2002; 62(3): 781 - 788.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Szepeshazi, A. V. Schally, G. Halmos, B. Sun, F. Hebert, B. Csernus, and A. Nagy
Targeting of Cytotoxic Somatostatin Analog AN-238 to Somatostatin Receptor Subtypes 5 and/or 3 in Experimental Pancreatic Cancers
Clin. Cancer Res., September 1, 2001; 7(9): 2854 - 2861.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halmos, G.
Right arrow Articles by Nagy, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halmos, G.
Right arrow Articles by Nagy, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals